¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"host range mutant"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • conversational range
    ȸȭÀ½¿ª
  • dynamic range
    ¿ªµ¿¹üÀ§, ¿îµ¿¹üÀ§
  • explosibility range
    Æø¹ß¹üÀ§
  • flammable range
    ÀÎÈ­¹üÀ§
  • frequency range
    Á֯ļö¹üÀ§
  • hearing range
    û¿ª, µè´Â¹üÀ§
  • inflammability range
    ÀÎÈ­¹üÀ§
  • melting range
    À¶ÇعüÀ§
  • percentile range
    ¹éºÐÀ§¼ö¹üÀ§
  • range
    1. ¹üÀ§, ¿µ¿ª 2. ºÐÆ÷¿ª
  • range ambiguity
    À½¿ªºÒºÐ¸í
  • range finder
    °Å¸®°è
  • range of motion
    ¿îµ¿¹üÀ§
  • range resolution
    °Å¸®ºÐÇØ´É
  • speech range
    ¾ð¾îÁÖÆÄ¿ª, È­¼º¿ª
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • virulent mutant
    µ¶¼ºµ¹¿¬º¯ÀÌÁÖ
  • accommodation range
    Á¶Àý¹üÀ§
  • range ambiguity
    À½¿ªºÒºÐ¸í¼º
  • close-range gunshot wound
    ±ÙÁ¢»çÃÑ»ó
  • conversational range
    ȸȭÀ½¿ª
  • dynamic range
    ¿ªµ¿¹üÀ§, ¿îµ¿¹üÀ§
  • explosibility range
    Æø¹ß¹üÀ§
  • flammable range
    ÀÎÈ­¹üÀ§
  • frequency range
    Á֯ļö¹üÀ§
  • range finder
    °Å¸®°è
  • hearing range
    û¿ª, µè´Â¹üÀ§
  • inflammability range
    ÀÎÈ­¹üÀ§
  • melting range
    À¶ÇعüÀ§
  • percentile range
    ÆíÂ÷
  • range
    ¹üÀ§, ¿µ¿ª, ºÐÆ÷¿ª
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • range
    ¹üÀ§ (ÛôêÌ)
  • range ambiguity
    À½¿ªºÒºÐ¸í¼º.
  • range ambiguity
    À½¿ªºÒºÐ¸í¼º
  • range finder
    Ãø°ÅÀÇ(ö´Ëåëð), °Å¸®°è(ËåìÆÍª).
  • range of accommodation
    Á¶Àý¹üÀ§(ðàï½çÐæ´).
  • range of audibility
    û¿ª
  • range of convergence
    ÆøÁÖ¹üÀ§(ÜßñÍÛôêÌ).
  • range of divergence
    ¹ß»ê¹üÀ§.
  • range of fusion
    À¶ÇÕ¹üÀ§
  • range of joint motion
    °üÀý ¿îµ¿ ¹üÀ§(μï½ê¡ÔÑÛôêÌ).
  • range of motion
    ¿îµ¿¹üÀ§(ê¡ÔÑÛôêÌ), ¿îµ¿ÇѰè(ê¡ÔÑùÚÍ£).
  • range of point
    ¿­Á¡(æïïÇ).
  • range of transition
    Àüȯ¹üÀ§.
  • range of variation
    º¯ÀÌÆø.
  • range of voice
    ¼º¿ª
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ(¡­ë¶îîí­).
  • mutant gene
    µ¹¿¬º¯ÀÌÀ¯ÀüÀÚ
  • mutant species
    µ¹¿¬º¯ÀÌÁ¾(ÔÍæÔܨì¶ðú).
  • mutant(s)
    º¯ÀÌü(ܨì¶ô÷).
  • mutant, conditional lethal
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
  • mutant, deletion
    °á¼ÕÇü µ¹¿¬º¯ÀÌÁÖ
  • mutant, temperature-sensitive
    ¿Âµµ °¨¼ö¼º µ¹¿¬º¯ÀÌÁÖ
  • nutritional mutant
    ¿µ¾çº¯ÀÌÁÖ(~ܨì¶ñ»).
  • temperature sensitive mutant
    ¿Âµµ¹Î°¨µ¹¿¬º¯ÀÌÁÖ(è®öôÚÂÊïÔÍæÔܨì¶ñ»).
  • temperature-sensitive mutant
    ¿Âµµ¹Î°¨[µ¹¿¬]º¯ÀÌÁÖ
  • virulent mutant
    µ¶¼º µ¹¿¬º¯ÀÌÁÖ
  • virulent mutant
    µ¶¼º(µ¹¿¬)º¯ÀÌ(±Õ)ÁÖ(¡­ÔÍæÔܨì¶Ð¶ñ»).
  • compromised host
    ÀúÇ×·Â ÀúÇϼ÷ÁÖ
  • definitive host =final h.
    ÃÖÁ¾¼÷ÁÖ(¡­âÖñ«).
  • final host
    ÃÖÁ¾¼÷ÁÖ, Á¾¼÷ÁÖ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 9 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • natural host
    ÀÚ¿¬°¨¿°¼÷ÁÖ
  • principal host
    ÁÖ¼÷ÁÖ
  • reservoir host
    º¸À¯¼÷ÁÖ
  • second intermediate host
    Á¦ÀÌÁß°£¼÷ÁÖ
  • susceptible host
    °¨¼ö¼º¼÷ÁÖ
  • transport host
    ¿î¹Ý¼÷ÁÖ
  • unnatural host
    ºñÈ£Àû¼÷ÁÖ
  • vector host
    ¸Å°³¼÷ÁÖ
  • vicarious host
    ´ë¸®¼÷ÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • asporogenous mutant
    Ȧ¾¾ºÒÇü¼º º¯ÀÌÁ¾ (ÝÕû¡à÷ ܨì¶ðú)
  • biochemically deficient mutant
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ) °áÇ̺¯ÀÌÁ¾(ÌÀù¹Ü¨ì¶ðú)
  • biochemical mutant
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ) º¯ÀÌÁ¾(ܨì¶ðú)
  • cofactor-requiring mutant
    º¸(Á¶)ÀÎÀڿ䱸 º¯ÀÌü(ÜÍ(ð¾)ì×í­é©Ï´Ü¨ì¶ô÷)
  • cold-sensitive mutant
    ³Ã¹Î°¨ º¯ÀÌü(Ò²ÚÂÊïܨì¶ô÷)
  • conditional lethal mutant
    Á¶°ÇºÎ Ä¡»çº¯ÀÌü(ðÉËìݾöÈÞÝܨì¶ô÷)
  • conditional mutant
    Á¶°ÇºÎ º¯ÀÌü(ðÉËìݾܨì¶ô÷)
  • cryptic mutant
    ÀáÀç º¯ÀÌü(íÖî¤Ü¨ì¶ô÷)
  • deficiency mutant
    "°áÇÌ º¯ÀÌü(ÌÀù¹Ü¨ì¶ô÷), (ÔÒ) auxotroph"
  • DNA-arrest mutant
    DNAÁ¤Áö(ïÎò­) º¯ÀÌü(ܨì¶ô÷)
  • DNA-delay mutant
    DNAÁöü º¯ÀÌü(òÀôòܨì¶ô÷)
  • DNA-negative mutant
    ¹«(Ùí)DNA º¯ÀÌü(ܨì¶ô÷)
  • dual-effect mutant
    ÀÌÁßÈ¿°ú º¯ÀÌü(ì£ñìüùÍýܨì¶ô÷)
  • leaky mutant
    ´©Ã⺯ÀÌü(שõóܨì¶ô÷)
  • maturation-defective mutant
    ¼º¼÷°áÇÔ º¯ÀÌÁ¾(à÷âÙÌÀùèܨì¶ðú)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
GVHD Graft-Versus-Host Disease; ½Ä´ëÁÖ Áúȯ
GVH, GvH graft-versus-host
GVHD, GvHD graft-versus-host disease
GVHR, GvHR graft-versus-host reaction
G vs HD graft versus host disease
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MF Mutant frequency
MUT mutant
MF mutant frequencies
TTR mutant transthyretin
IR Interquartile Range
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • range of divergence
    ¹ß»ê ¹üÀ§
  • range of motion
    ¿îµ¿ ¹üÀ§, ¿îµ¿ ÇѰè
    °üÀýÀÌ Æî ¼ö ÀÖ´Â ¿øÀÇ °¢µµ¸¦ ÃøÁ¤ÇÑ ¹üÀ§·Î¼­ ÀϹÝÀûÀ¸·Î ÃøµÎÇϾǰüÀý¿¡¼­´Â °¢µµº¸´Ù´Â ÀýÄ¡ °£ ÇÏ¾Ç È°ÁÖ¸¦ ¹Ì¸®¹ÌÅÍ·Î º¸°íÇÑ´Ù.
  • range-of motion exercise
    ¿îµ¿ ¹üÀ§ ³» ¿îµ¿ ¿ä¹ý
  • sensitivity range
    ¹Î°¨µµ ¹üÀ§
  • specular range
    ±¤ÇÐ ¹üÀ§
  • wide dynamic range
    ±¤µ¿¹üÀ§, ±¤µ¿Àû ¹üÀ§
  • wide dynamic range neuron
    ±¤µ¿¹üÀ§ ´º¿ì·±, ±¤µ¿Àû ¹üÀ§ ´º¿ì·±
  • wide dynamic range response characteristics
    ±¤µ¿¹üÀ§ ¹ÝÀÀ Ư¡, ±¤µ¿Àû ¹üÀ§ ¹ÝÀÀ Ư¡
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
parasite-host ecosystem Complex of all parasite species and individuals associated with a specific host.
Synonym: parasite-host ecosystem.
Origin: parasite + G. Koinos, common, together
(05 Mar 2000)
paratenic host An intermediate host in which no development of the parasite occurs, although its presence may be required as an essential link in the completion of the parasite's life cycle; e.g., the successive fish host's that carry the plerocercoid of Diphyllobothrium latum, the broad fish tapeworm, to larger food fish eventually eaten by man or other final host's.
Synonym: transport host.
(05 Mar 2000)
reservoir host The host of an infection in which the infectious agent multiplies and/or develops, and upon which the agent is dependent for survival in nature; the host essential for the maintenance of the infection during times when active transmission is not occurring.
(05 Mar 2000)
graft-versus-host disease <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host reaction <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
cutaneous graft versus host reaction An acute erythematous maculopapular reaction with bulla formation in the most severe cases; chronic changes may resemble lichen planus or scleroderma.
(05 Mar 2000)
secondary host <epidemiology> See vector.
(05 Dec 1998)
host An organism that is infected with or is fed upon by a parasitic or pathogenic organism (for example, a virus, nematode, fungus). The term can also be applied, loosely, to a plant supporting an epiphyte.
(09 Oct 1997)
host cell A cell which has been infected by a virus is known as the host cell of that virus.
A cell which is used in lab techniques such as DNA cloning to receive, maintain, and allow the reproduction of recombinant DNA cloning vectors. The DNA introduced with the vector is replicated whenever the cell divides and the recombinant proteins encoded for by the plasmid are reproduced in large quantities.
(13 Nov 1997)
host-parasite relations The interactions between two organisms, one of which lives at the expense of the other.
(12 Dec 1998)
host restriction-modification A bacterial system where the bacterium is able to destroy invading DNA from a bacteriophage (virus which infects bacteria) while at the same time preventing the destruction of their own DNA. The phage DNA is cleaved by a restriction enzyme made by the bacterium, the bacterial DNA is modified (usually with methylation) so that the enzyme will not destroy it.
(09 Oct 1997)
host-vector system A combination of a bacterial host cell (i.e. A specific strain) and a virus vector (i.e. A particular bacteriophage strain) which work well together for DNA cloning.
(09 Oct 1997)
host versus graft reaction The normal lymphocyte mediated reactions of a host against allogeneic or xenogeneic cells acquired as a graft or otherwise, which lead to damage or/and destruction of the grafted cells. The opposite of graft-versus-host reaction. The common basis of graft rejection.
(18 Nov 1997)
host vs graft reaction The immune responses of a host to a graft. A specific response is graft rejection.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 14 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gas range
    (¿ä¸®¿ë)°¡½º ·¹ÀÎÁö
  • home range
    (Á¤ÁÖ¼ºµ¿¹°ÀÇ)Çൿ±Ç
  • intermediate range ballistic missile
    Á߰Ÿ® ŸµµÅº
  • mountain range
    »ê¸Æ;»ê¾Ç Áö¹æ
  • radio range
    (Ç×°ø±âÀÇ)¹«¼± Ç׷ΠǥÁö
  • range
    (...ÀÇ) ¹üÀ§¸¦ Á¤ÇÏ´Ù;¹èȸÇÏ´Ù;ã¾Æ Çì¸Å´Ù;(¿¬¾ÈÀ»)¼øÇ×ÇÏ´Ù;Æíµé´Ù;°©ÆÇÀ§·Î Ç®¾î³»´Ù(´éÀÇ Ã¼Àεî);ÇÑÁÙ·Î ´Ã¾î¼­´Ù;(»ê¸Æ µîÀÌ)¿¬ÇØ ÀÖ´Ù;»¸´Ù;(µ¿½Ä¹°ÀÌ)ºÐÆ÷ÇÏ´Ù;(¹°°ÇÀ» ã¾Æ¼­)Çì¸Å´Ù;¹æÈ²ÇÏ´Ù;º¯È­ÇÏ´Ù;(¿Âµµ°è µîÀÌ)¿À¸£³»¸®´Ù;ÆòÇàÇÏ´Ù;¾î±ú¸¦ ³ª¶õÈ÷ ÇÏ´Ù;(ź
  • range
    ¿­;ÀÕ´êÀ½;ÁÙÁöÀ½;°è¼Ó;»ê¸Æ;¿¬¼Ó(°°Àº Á¾·ùÀÇ °ÍÀÇ);Á¶;¸ðÀÓ;(»ð¾Æ 6¸¶ÀÏÀÇ)½Ã±º;¹üÀ§;±¸¿ª;³ÐÀÌ;ºÐÆ÷ ±¸¿ª(µ¿½Ä¹°ÀÇ);¼­½Ä±â;¹«¼º±â;(ÇØÁß µ¿¹°ÀÌ »ç´Â)¹°ÀÇ ±íÀÌ;¼­½Ä ¹üÀ§;»çÁ¤;Ç×¼Ó °Å¸®;À½¿ª;½Ã°è;Áö½Ä¹üÀ§;»ç°ÝÀå;¹Ì»çÀÏ;½ÇÇèÀå;¹æ¸ñ±¸¿ª;¸ñÀå;(°°Àº Á¾·ùÀÇ)µµ±¸ ÇÑ
  • range finder
    °Å¸® ÃøÁ¤±â(°è)
  • range oil
    ·¹ÀÎÁö(Ãë»ç¿ë ³­·Î)¿ë ±â¸§
  • range pole
    Ãø·®´ë;Æú
  • rifle range
    (¼ÒÃÑ)»ç°ÝÀå;¼ÒÃÑ »çÁ¤
  • rocket range
    ·ÎÄÏ ¹ß»ç ½ÃÇèÀå
  • sheep range
    ¾ç ¹æ¸ñÀå
  • shooting range
    »ç°ÝÀå
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á